Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?
Postel-Vinay S, Boursin Y, Massard C, Hollebecque A, Ileana E, Chiron M, Jung J, Lee JS, Balogh Z, Adam J, Vielh P, Angevin E, Lacroix L, Soria JC. Postel-Vinay S, et al. Ann Oncol. 2016 Feb;27(2):344-52. doi: 10.1093/annonc/mdv570. Epub 2015 Nov 23. Ann Oncol. 2016. PMID: 26598538 Free article. Clinical Trial.
Translational Aspects of Epithelioid Sarcoma: Current Consensus.
Grünewald TGP, Postel-Vinay S, Nakayama RT, Berlow NE, Bolzicco A, Cerullo V, Dermawan JK, Frezza AM, Italiano A, Jin JX, Le Loarer F, Martin-Broto J, Pecora A, Perez-Martinez A, Tam YB, Tirode F, Trama A, Pasquali S, Vescia M, Wortmann L, Wortmann M, Yoshida A, Webb K, Huang PH, Keller C, Antonescu CR. Grünewald TGP, et al. Clin Cancer Res. 2024 Mar 15;30(6):1079-1092. doi: 10.1158/1078-0432.CCR-23-2174. Clin Cancer Res. 2024. PMID: 37916971 Free PMC article. Review.
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study.
Postel-Vinay S, Collette L, Paoletti X, Rizzo E, Massard C, Olmos D, Fowst C, Levy B, Mancini P, Lacombe D, Ivy P, Seymour L, Le Tourneau C, Siu LL, Kaye SB, Verweij J, Soria JC. Postel-Vinay S, et al. Eur J Cancer. 2014 Aug;50(12):2040-9. doi: 10.1016/j.ejca.2014.04.031. Epub 2014 May 28. Eur J Cancer. 2014. PMID: 24880774
Phase I trials in oncology: a new era has started.
Postel-Vinay S, Soria JC. Postel-Vinay S, et al. Ann Oncol. 2015 Jan;26(1):7-9. doi: 10.1093/annonc/mdu513. Epub 2014 Oct 30. Ann Oncol. 2015. PMID: 25361990 Free article. No abstract available.
Targeting FGFR Signaling in Cancer.
Touat M, Ileana E, Postel-Vinay S, André F, Soria JC. Touat M, et al. Clin Cancer Res. 2015 Jun 15;21(12):2684-94. doi: 10.1158/1078-0432.CCR-14-2329. Clin Cancer Res. 2015. PMID: 26078430 Review.
117 results